Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPreventive Services & ScreeningBlue Cross Blue Shield NC Cervical Screening Cover…
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - North CarolinaPolicy N/A

    Cervical Cancer Screening

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

    Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and reimbursement criteria for cervical cancer screening (Pap cytology, high-risk HPV testing, and co-testing) for individuals with a cervix under Blue Cross Blue Shield of North Carolina.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyCervical Cancer Screening
    Policy CodePolicy N/A
    Change TypeCriteria clarifications and coding additions
    Effective DateApr 1, 2019
    Last ReviewFeb 11, 2026
    Next Review DateOct 1, 2025
    Key ActionVerify member benefits and document age, risk status, and prior screening history to support coverage.
    SourceLink
    POLICY UPDATE CHANGES

    Separated statement in When Not Covered to make two statements that now read: 'Reimbursement is not allowed for testing for low-risk HPV.' and 'Reimbursement is not allowed for all other indications not discussed above for cervical screening.'

    Coverage criteria #1 edited to include immunocompromised, therefore removed immunocompromised from coverage criteria #4 and #6.

    Coverage criteria 1a changed from individuals under 30 to individuals of all ages; added 'high-risk' to coverage criteria 1b; edited coverage criteria #5 to add 'nucleic acid' for clarity.

    Added CPT code 87626 to Billing/Coding section, effective 1/1/2025.

    Added 0502U to Billing/Coding section, effective 10/1/24.

    21-29age range with recommended Pap every 3 years
    30-65age range with multiple acceptable screening options
    >65screening generally discontinued if not high-risk
    Annualrecommended annual cytology for special-risk groups
    Teal WandFDA-authorized at-home device referenced
    2019-04-01effective date (policy implemented)

    Coverage Criteria for Cervical Cancer Screening

    Covered screening by age and risk

    Covered when ALL of the following age- and risk-specific criteria are met:

    Immunocompromised or immunosuppressed individuals: Annual cervical cytology testing for individuals of all ages OR co-testing (cervical cytology + high-risk HPV testing) once every 3 years for individuals 30 years of age or older is allowed.annual or q3y

    Immunocompromised or immunosuppressed status permits more frequent screening per policy.

    Individuals 21 to 29 years: Reimbursement allowed for cervical cancer screening once every 3 years using conventional or liquid-based Papanicolaou (Pap) smears.q3y

    Applies to average-risk, asymptomatic, immunocompetent individuals.

    Individuals 30 to 65 years: Reimbursement allowed using any one of: (1) conventional or liquid-based Pap smear once every 3 years; (2) high-risk HPV (hr-HPV) testing alone once every 5 years; (3) co-testing (cytology with concurrent hr-HPV testing) once every 5 years.q3y or q5y depending on method

    Multiple acceptable screening modalities per policy.

    Individuals over 65 who are high-risk (history of high-grade precancerous lesion or cervical cancer, or in utero DES exposure) are allowed screening at the frequency described for individuals 30–65 years of age.follow 30–65 criteria

    High-risk exception to general cessation of routine screening.

    Pooled hr-HPV positive individuals: Reimbursement allowed for nucleic acid testing for high-risk strains HPV-16 and HPV-18 for individuals who are pooled hr-HPV positive.as clinically indicated

    Genotyping for HPV-16/18 allowed following a pooled positive hr-HPV result.

    Individuals ≤65 with prior abnormal results or other high-risk indications: Annual cervical cancer screening by Pap smear or hr-HPV testing is allowed for individuals 65 years of age or younger who had a previous abnormal cytology result and/or were positive for HPV, or who are high-risk (e.g., organ transplant, in utero DES exposure).annual

    Applies to those with prior abnormal results or other defined high-risk status.

    Screening and management criteria

    Coverage-aligned screening recommendations from cited guideline bodies (USPSTF, ACS, ASCCP, NCCN, NCI, ACOG) summarized as criteria sets

    Average-risk screening ages 21-29: For individuals aged 21–29: cytology (Pap) every 3 years.

    Per USPSTF and reflected in policy.

    Average-risk screening ages 30-65: For individuals aged 30–65: one of - cytology every 3 years OR high-risk HPV testing alone every 5 years OR co-testing (cytology + hr-HPV) every 5 years.

    Per USPSTF (2018) and ACS (2020) guidance.

    No routine screening: Do not screen individuals younger than 21, older than 65 with adequate prior screening, or those without a cervix after hysterectomy for benign disease.

    Per USPSTF and NCI recommendations.

    Immunocompromised and transplant recipients:

    Guideline-based coverage and triage criteria

    Guideline-based recommendations and triage algorithms summarized from multiple specialty societies and public health agencies.

    Primary hrHPV screening age and interval: Primary hrHPV screening should not be initiated before age 25; after a negative primary hrHPV test, rescreen no sooner than every 3 years; some organizations recommend HPV DNA screening every 5 years for ages 25–65 (or 30–65 depending on guideline).age >=25; interval >=3 years or 5 years per guideline

    Interim 2015 guidance and subsequent society statements support these intervals.

    Triage for positive HPV tests: All positive primary HPV screening tests should have reflex triage testing from the same specimen (eg, reflex cytology); HPV16/18 (and sometimes HPV45) genotyping indicates higher risk and typically prompts colposcopy even if cytology is negative. If reflex testing is not feasible for HPV16/18 positive results, proceed directly to colposcopy.HPV16/18 positive triggers colposcopy

    ACOG, CDC, ASCO and ASCCP guidance emphasize genotyping and reflex testing to determine colposcopy referral.

    When Covered / General criteria

    Policy provides coverage when medical necessity criteria and guidelines are met; coverage criteria were updated and clarified over time.

    General coverage stance: BCBSNC will provide coverage for cervical cancer testing when it is determined to be medically necessary because the medical criteria and guideline-based recommendations are met.

    Policy implementation and subsequent updates document this coverage stance and clarifications.

    Reimbursement is not allowed for cervical cancer screening (cervical cytology or hr‑HPV testing) for individuals younger than 21 years except where specific covered exceptions are separately addressed. The policy also states that routine screening is not allowed for individuals >65 years of age who are not immunocompromised, immunosuppressed, or otherwise considered high‑risk for cervical cancer. Claims performed outside these age‑based boundaries may be denied.

    Screening is not recommended and reimbursement is not allowed for individuals who have undergone hysterectomy with removal of the cervix for benign disease and who have no history of cervical cancer or precancer; guideline sources conclude screening in persons without a cervix is not helpful and should not be performed.

    Primary high‑risk HPV (hrHPV) screening should not be initiated before age 25. When used as primary screening, a negative hrHPV test should prompt rescreening no sooner than every 3 years; some guideline bodies recommend hrHPV DNA screening at up to 5‑year intervals for specified age groups. For persons at higher risk (for example, immunocompromised individuals or others identified in guideline tables), screening may be started earlier and performed more frequently (for many of these individuals, annual cytology or tailored co‑testing is recommended).

    Reimbursement is not allowed for testing that targets low‑risk HPV types (the genotypes associated with genital warts); professional guidance (Choosing Wisely/AAFP) states low‑risk HPV testing has no medical indication and should not be performed.

    Reimbursement is not allowed for other indications for cervical screening that are not explicitly described as covered in this policy. The policy lists multiple not‑covered situations (see the When Covered section for the allowed, age‑ and risk‑specific criteria); testing performed for indications outside those criteria may be denied.

    Routine cervical cancer screening is generally discontinued after age 65 for persons who are not immunocompromised, immunosuppressed, or otherwise high‑risk, provided they have had adequate prior screening. The USPSTF and policy language indicate screening beyond this age in average‑risk individuals is considered not beneficial and is typically not covered.

    Consistent with USPSTF guidance, routine screening is not recommended for individuals younger than 21 or for those older than 65 with adequate prior screening. These age‑based limits reflect guideline assessments that screening in these groups provides no net benefit and may increase harms from false positives and unnecessary procedures.

    Choosing Wisely/American Academy of Family Physicians recommends against low‑risk HPV testing (HPV types that cause genital warts). The policy adopts this stance and specifies that low‑risk HPV testing is not medically indicated and is not reimbursed.

    Historical policy changes: prior age‑based restrictions that limited reimbursement for individuals under 21 only to specific high‑risk situations were removed effective 12/5/2023. The policy language was updated to clarify coverage criteria and to separate noncoverage statements for low‑risk HPV testing and other non‑covered indications.

    Billing and Applicable Service Codes

    Applicable service codesmixed
    0502U
    87623
    87624
    87625
    87626
    88141
    88142
    88143
    88147
    88148
    1–10 of 31
    1/4
    Applicable service codesmixed
    0502UApplicable service code
    87623HPV test (code listed as applicable)
    87624HPV test (applicable)
    87625HPV test (applicable)
    87626HPV test (added to Billing/Coding effective 1/1/2025)
    88141Cervical cytology codes (applicable)
    88142Cervical cytology codes (applicable)
    88143Cervical cytology codes (applicable)
    88147Cervical cytology codes (applicable)
    88148Cervical cytology codes (applicable)
    1–10 of 31
    1/4

    Provider Actions, Documentation, and Billing Guidance

    Prior Authorization

    Prior authorization

    No prior authorization statements are present in this portion of the policy.

    Documentation Required

    Expedited treatment — document risk assessment & counseling

    Expedited treatment (treatment without a preceding colposcopic biopsy demonstrating CIN2+) is preferred for selected nonpregnant patients ≥25 years (for example HSIL cytology with concurrent HPV‑16) when immediate CIN3+ risk meets thresholds; document shared decision‑making, risk assessment, and counseling in the medical record.

    • Expedited treatment is preferred when immediate risk of CIN3+ ≥60% and acceptable for risks 25–60%.
    • Document counseling and risk assessment; expedited treatment is only possible if cytology is performed (so reflex cytology must be available).

    Background and Rationale

    Cervical cancer screening aims to detect precancerous lesions and invasive disease using cytology (Pap), high‑risk HPV testing, and colposcopy when indicated. High‑risk HPV types, particularly HPV‑16 and HPV‑18, are strongly associated with cervical intraepithelial neoplasia and cervical cancer. Screening intervals and modality selection vary by age and risk: for example, cytology every 3 years for ages 21–29, and for ages 30–65 either cytology every 3 years, hr‑HPV testing alone every 5 years, or co‑testing every 5 years. Colposcopy with biopsy is the diagnostic follow‑up when screening or triage testing indicates high risk, and reflex cytology or triage testing from the same specimen is recommended for positive primary hrHPV results to guide management.

    Definitions and Key Terms

    inv-33: Co-testing — concurrent cervical cytology and high-risk HPV testing
    DefinitionConcurrent cervical cytology (Pap) and high-risk HPV (hr-HPV) testing performed at the same visit on the same individual.
    Allowed interval (age 30–65)Co-testing (cytology + hr-HPV) once every 5 years is an accepted screening option.
    Use in immunocompromisedCo-testing once every 3 years is allowed for immunocompromised or immunosuppressed individuals aged 30 years or older.
    Preferred specimen handlingCytology and hr-HPV testing should ideally be performed from clinician-collected cervical specimens; reflex testing from the same specimen is recommended when indicated.
    inv-34: hr-HPV — high-risk HPV definition and examples (HPV-16, etc.)
    Definition
    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyCervical Cancer Screening
    Policy CodePolicy N/A
    Change TypeCriteria clarifications and coding additions
    Effective DateApr 1, 2019
    Last ReviewFeb 11, 2026
    Next Review DateOct 1, 2025
    Key ActionVerify member benefits and document age, risk status, and prior screening history to support coverage.
    SourceLink
    On This Page
    Coverage Criteria for Cervical Cancer ScreeningBilling and Applicable Service CodesProvider Actions, Documentation, and Billing GuidanceBackground and RationaleDefinitions and Key Terms
    Start screening earlier and perform more frequent screening (often annual cytology if using cytology alone; co-testing preferred if ≥30; continue screening beyond age 65 with individualized decision-making).

    ASCCP 2019 guidance for non-HIV immunocompromised women (see policy tables).

    Management of HPV-positive primary screening: All positive primary HPV screening tests should have reflex triage testing (e.g., cytology) from the same specimen; if reflex testing is not feasible, proceed to colposcopy and collect the additional triage specimen at that visit.

    Per ACOG and CDC recommendations and ASCCP management guidance.

    Self-sampling: Clinician-collected cervical specimens are preferred; self-collected vaginal specimens are acceptable for asymptomatic, average-risk screening. If self-sample HPV negative, repeat in 3 years; if positive for HPV 16/18, refer to colposcopy with concurrent cytology collection; other HR results may require clinician-collected specimen for cytology/dual-stain.

    Enduring Consensus 2025 update recommendations and ASCCP statements.

    Surveillance after treatment of HSIL/CIN2/3/AIS: Continued surveillance with HPV testing or cotesting at 3-year intervals for at least 25 years after treatment and initial post-treatment management of histologic HSIL, CIN2, CIN3, or AIS; continuation beyond 25 years acceptable based on life expectancy and ability to be screened.surveillance every 3 years for >=25 years post-treatment

    ACOG recommends prolonged surveillance after treatment due to persistent elevated risk.

    Management intervals for special populations (HIV): Women with HIV: ages 21–29 have Pap at baseline and every 12 months; if three consecutive normal Pap tests, follow-up every 3 years. Women with HIV ≥30 may have annual Pap testing or baseline co-testing with 3-year interval if both negative; positive HPV16/18 prompts colposcopy.HIV-specific intervals and triggers

    US HHS HIV OI guidelines summarized in policy.

    Resource-stratified ASCO recommendations: ASCO provides screening ages and intervals by resource setting (e.g., maximal-resource: HPV DNA every 5 years age 25–65; enhanced-resource: HPV DNA every 5 years age 30–65) and specific triage/treatment algorithms including repeat testing at 12 months and use of ablation or LEEP for precancerous lesions.varies by resource setting

    ASCO 2022 resource-stratified guidance.

    Billing Rule

    Applicable service codes listed — verify reimbursement

    Applicable service codes are listed in the Billing/Coding section but inclusion does not guarantee reimbursement; verify reimbursement rules and any administrative/prior authorization requirements with BCBSNC.

    • Listed applicable service codes include: 0502U, 87623–87626, multiple cytology CPT/HCPCS codes, and others (see billing/coding list).
    • Check BCBSNC Administrative Policies and the member benefit for coverage and reimbursement details.
    Billing Rule

    Applicable service codes — verify benefits & medical necessity

    Inclusion of codes in the billing/coding list indicates applicable service codes but presence in the list does not guarantee payment; verify member benefits and medical necessity for each claim.

    • The policy explicitly states that inclusion of a code does not guarantee reimbursement.
    • Confirm coverage in the Member's Benefit Booklet and BCBSNC administrative policies before billing.
    Note

    Provider action (reserved)

    (No provider action content provided in source for this placeholder.)

    Step Therapy

    HPV‑16/18 positive — refer for colposcopy with biopsy

    When HPV‑16 or HPV‑18 is detected, additional diagnostic evaluation such as colposcopy with biopsy is recommended even if cytology is negative; if reflex testing from the same specimen is not feasible, proceed directly to colposcopy and collect triage specimens at that visit.

    • HPV‑16 and HPV‑18 infections have the highest risk for CIN3 and occult cancer and typically prompt colposcopy even with NILM cytology.
    • If HPV16/18 positive and same‑sample additional testing is not feasible, patients should proceed directly to colposcopy.
    Billing Rule

    Applicable service codes — confirm coverage

    Additional applicable service codes are listed in the billing/coding section; inclusion does not guarantee reimbursement—confirm with BCBSNC and member benefits.

    Billing Rule

    Applicable service codes — verify before billing

    Additional applicable service codes are listed in the billing/coding section; presence on the list does not ensure payment—verify benefits and medical necessity prior to billing.

    Documentation Required

    Benefit verification and clinical documentation

    Verify the member's benefit design in the Member's Benefit Booklet prior to applying policy criteria and document clinical indications, age, risk status, and prior screening history in the medical record to support coverage.

    • Document clinical indication, patient age, risk factors (e.g., immunocompromised status, prior abnormal cytology, DES exposure), and prior screening history.
    • Confirm benefit availability in the Member's Benefit Booklet as member benefits may vary by plan.
    Documentation Required

    Reflex triage testing — use same specimen or collect at colposcopy

    For primary HPV screening, perform reflex cytology or other triage testing from the same laboratory specimen for all positive HPV tests; if same‑specimen reflex testing is not feasible, proceed to colposcopy and collect the additional triage specimen at that visit.

    • Reflex triage testing from the same specimen is recommended because results inform colposcopy practice and management.
    • Reflex cytology is required to enable expedited treatment decisions when indicated.
    Documentation Required

    Medical records may be requested — letters alone often insufficient

    BCBSNC may request medical records to determine medical necessity; letters alone are insufficient unless they include all information needed for a medical necessity determination.

    • Maintain complete medical records supporting the indication for screening and any abnormal results, diagnostic procedures, and counseling.
    • Letters of support may be useful but must include all required clinical details to substitute for records.
    Documentation Required

    Supporting documentation — include all required clinical details

    When medical records are requested, letters of support or explanation may be useful but are not sufficient unless they include all specific information needed to make a medical necessity determination; ensure records include relevant clinical details.

    • Include specific clinical information (age, risk factors, prior screening/results, reason for test) in records or letters if submitted.
    • Failure to provide requested documentation can result in denial or nonpayment.
    Denial Risk

    Triggers for denial — screening performed in excluded situations

    Claims for cervical cancer screening can be denied when the service is performed for individuals under age 21 (except as specifically addressed), for routine screening in individuals over 65 who are not high‑risk, for individuals post‑hysterectomy with no history of cervical cancer/precancer, for testing for low‑risk HPV, or for other indications not listed as covered.

    • Do not submit claims for routine screening for individuals <21 (unless an exception in policy applies).
    • Do not submit routine screening claims for individuals >65 who are not high‑risk (had adequate prior screening).
    • Do not bill for low‑risk HPV testing—reimbursement is not allowed.
    Denial Risk

    Age‑based screening limits — follow guideline age ranges

    Screening outside the recommended age ranges (younger than 21 or older than 65 with adequate prior screening) is discouraged and may result in noncoverage or denial depending on benefit rules; follow USPSTF/other guideline age limits when applying for coverage.

    • USPSTF recommends against routine screening for individuals younger than 21 and older than 65 with adequate prior screening.
    • Confirm exceptions (e.g., high‑risk individuals) and document rationale when screening outside typical age ranges.
    Billing Rule

    Codes listed do not guarantee payment — retain supporting documentation

    Inclusion of a code in the billing/coding section does not guarantee reimbursement; BCBSNC may request medical records to determine medical necessity, so retain documentation supporting the billed service.

    • Keep complete medical records showing clinical indication, prior screening history, and risk status.
    • Verify reimbursement and any prior authorization requirements before submitting claims.
    Denial Risk

    Medical records may be requested — missing documentation risks denial

    BCBSNC may request medical records for determination of medical necessity; absence of required documentation can trigger denial or nonpayment. Ensure medical records fully document the indication, findings, and management.

    • Document age, risk factors, prior screening results, reason for testing, and any reflex or follow‑up testing performed.
    • Provide requested records promptly to avoid denial or delays in payment.
    High-risk HPV (hr-HPV) refers to HPV genotypes associated with cervical cancer and its precursors; testing detects viral nucleic acid from carcinogenic strains.
    ExamplesIncludes notably HPV-16 and HPV-18 among other carcinogenic types detected by FDA-approved assays.
    Testing purposehr-HPV testing is used to identify infections with elevated risk for CIN2+ and cervical cancer to guide triage and management.
    ExclusionsTesting for low-risk HPV (types causing genital warts) is not reimbursed per policy.
    inv-35: Primary hrHPV screening — definition and use as primary modality
    DefinitionPrimary hrHPV screening is using a test that detects high-risk HPV types (with or without genotyping) alone as the first-line cervical cancer screening modality, without initial cytology.
    Minimum agePrimary hrHPV screening should not be initiated prior to age 25 per interim guidance; some guidelines reference age 25 or 30 depending on resource setting.
    Rescreen interval after negative testRescreen no sooner than every 3 years after a negative primary hrHPV test; some organizations recommend intervals of up to 5 years depending on guideline and age group.
    Reflex testingAll positive primary HPV screening tests should have reflex triage testing (e.g., cytology) from the same specimen to inform management.
    inv-36: Expedited treatment — definition for treating without preceding biopsy (when indicated)
    DefinitionExpedited treatment: treatment delivered without a preceding colposcopic biopsy demonstrating CIN2+ (i.e., treatment offered based on screening/triage risk assessment rather than confirmatory biopsy).
    IndicationsPreferred for nonpregnant patients ≥25 years with HSIL cytology and concurrent HPV-16 positivity when immediate risk of CIN3+ is ≥60%; acceptable for risks between 25%–60% in shared decision-making contexts.
    PrerequisitesExpedited treatment requires cytology to have been performed (to allow HSIL interpretation) and documentation of risk-based counseling and shared decision-making, especially regarding fertility/pregnancy implications.
    inv-37: Self-collected vaginal specimen — definition and acceptability for asymptomatic, average-risk screening
    DefinitionA self-collected vaginal specimen is a vaginal sample obtained by the individual (self-sampling) for HPV testing, used for cervical cancer screening in asymptomatic, average-risk persons with a cervix.
    AcceptabilityClinician-collected cervical specimens are preferred, but self-collected vaginal specimens are acceptable for screening in asymptomatic, average-risk individuals.
    Management of negative resultIf a self-collected vaginal specimen is HPV negative in the screening setting, repeat testing in 3 years is recommended.
    Management of positive resultIf positive for HPV 16 and/or 18, direct referral for colposcopy with concurrent cytology collection is recommended; other hr-HPV results may require clinician-collected specimen for cytology or dual-stain testing per guidance.
    inv-38: primary hrHPV testing — definition (test detecting hrHPV types alone as first-line)
    DefinitionPrimary hrHPV testing: a screening approach where a test that detects high-risk HPV types alone is used as the first-line screen without initial cytology.
    Age thresholdPrimary hrHPV screening should not be initiated prior to age 25 per interim guidance; some societies recommend starting at age 25 or 30 depending on guideline.
    Post-test actionsAll positive primary hrHPV tests should have reflex cytology or other triage testing from the same specimen; HPV16/18 positivity typically prompts colposcopy even if cytology is negative.
    inv-39: NAAT — nucleic acid amplification test definition for detecting HPV DNA/mRNA
    DefinitionNucleic acid amplification test (NAAT): a molecular assay (FDA-approved examples include assays detecting HPV DNA or mRNA) used to qualitatively detect specified high-risk HPV genotypes.
    FDA examplesFDA-approved NAAT assays referenced include APTIMA (detects mRNA for HPV 16, 18, 45 and earlier APTIMA for 14 high-risk types), COBAS (detects 14 high-risk types and can genotype 16/18), and BD Onclarity (detects 14 high-risk types including 16 and 18).
    Use in policyNAAT methods are the basis for hr-HPV testing used in primary screening, co-testing, and genotyping for HPV16/18 when clinically indicated.
    inv-40: High-risk HPV — definition and policy clarification
    DefinitionHigh-risk HPV refers to HPV genotypes associated with increased risk of cervical intraepithelial neoplasia and cervical cancer; testing detects these carcinogenic types to guide screening and management.
    High-risk strains of particular concernHPV-16 and HPV-18 have the highest risk for CIN3+ and occult cancer and often trigger more aggressive diagnostic evaluation when detected.
    Role in managementDetection of high-risk HPV guides triage (reflex cytology, genotyping) and decisions such as referral to colposcopy or expedited treatment per guideline-recommended risk thresholds.
    Policy clarificationPolicy language specifies coverage and reimbursement for testing that targets high-risk HPV; testing for low-risk HPV is not reimbursed.